(Q37076343)

18 August 2017

1 reference

title

Irregular gastrointestinal drug absorption in Parkinson's disease (English)

1 reference

18 August 2017

1 reference

1 reference

Dag Nyholm

1

1 reference

18 August 2017

Hans Lennernäs

series ordinal

2

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

Expert Opinion on Drug Metabolism & Toxicology

18 August 2017

published in

1 reference

18 August 2017

volume

4

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

193-203

1 reference

Prevalence and incidence of Parkinson's disease in Europe

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Bowel movement frequency in late-life and incidental Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Transit of pharmaceutical dosage forms through the small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Impact of the motor complications of Parkinson's disease on the quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Comparative gene expression profiles of intestinal transporters in mice, rats and humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

The effects of a normal protein diet on levodopa plasma kinetics in advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Gastric emptying time and gastric motility in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Human intestinal permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

The interdigestive myo-electric complex of the stomach and small bowel of dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Human interdigestive and postprandial gastrointestinal motor and gastrointestinal hormone patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Mechanism of gastric emptying of a nondisintegrating radiotelemetry capsule in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Effects of ageing on gastrointestinal motor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Influence of food on the absorption of acetylsalicylic acid from enteric-coated dosage forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Correlation of the gastric emptying of nondisintegrating tablets with gastrointestinal motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Twenty four hour manometric recording of colonic motor activity in healthy man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Intestinal permeability and orocaecal transit time in elderly patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Gastric emptying in Parkinson's disease: patients with and without response fluctuations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Predictors of gastric emptying in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Medical problems of marathon runners

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Basic and clinical pharmacology of new motility promoting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Promotility medications--now and in the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Gastrointestinal motility problems in patients with Parkinson's disease. Effects of antiparkinsonian treatment and guidelines for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Domperidone: a peripherally acting dopamine2-receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Antiparkinsonian agents. Drug interactions of clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

The influence of levodopa on gastric emptying in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Protein redistribution diet remains effective in patients with fluctuating parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Variable absorption of carbidopa affects both peripheral and central levodopa metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Using liquid levodopa in the treatment of Parkinson's disease. A practical guide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

The effect of ascorbic acid on the pharmacokinetics of levodopa in elderly patients with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Advances in the delivery of treatments for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Novel pharmacological targets for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Deep brain stimulation and continuous dopaminergic stimulation in advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

New levodopa sustained-release floating minitablets coated with insoluble acrylic polymer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.193

21 January 2018

Identifiers

DOI

10.1517/17425255.4.2.193

1 reference

18 August 2017

1 reference